Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Avelumab in Upper Tract Urothelial Carcinoma
NCT07225374Phase 2Recruiting
- Sponsor
- Samsung Medical Center
- Start
- Sep 2025
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in upper tract urothelial carcinoma (UTUC), sponsored by Samsung Medical Center. Primary endpoint: Disease-free survival at 1 year. Started Sep 2025; status: recruiting.
02
Drugs
avelumab
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT07225374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07225374.